EGFR and non-small cell lung carcinoma: Early and accurate identification of patients with EGFR mutations may support the timely initiation of tyrosine kinase inhibitors (TKIs), which have demonstrated improved outcomes in mutation-positive NSCLC patients [50,51,52].